```html

Klebsiella pneumoniae (Carbapenem‑Resistant)

Overview

Klebsiella pneumoniae is a gram‑negative, rod‑shaped bacterium that normally lives in the intestinal tract of healthy people. Certain strains have acquired resistance to carbapenems—broad‑spectrum antibiotics that are often the “last line” of defense against serious infections. When these carbapenem‑resistant Klebsiella pneumoniae (CRKP) strains cause disease, they are especially difficult to treat and can lead to high mortality rates.

• Who it affects: Adults older than 65, newborns, patients with weakened immune systems, and people who have been hospitalized for prolonged periods.
• Prevalence: In the United States, the CDC reported ~13,000 invasive CRKP infections and ~1,100 deaths in 2022, a 7‑% increase from 2019.<sup>[1]</sup> Worldwide, the incidence varies from 0.5 % to 2 % of all Klebsiella isolates in intensive‑care units (ICUs), with higher rates in regions with limited antibiotic stewardship.<sup>[2]</sup>
• Transmission: Primarily through direct contact with contaminated hands, surfaces, or medical equipment. Outbreaks are common in intensive care units, long‑term care facilities, and dialysis centers.

Symptoms

CRKP can cause a range of infections. The clinical picture often mirrors that of non‑resistant Klebsiella, but the severity may be greater because effective antibiotics are limited.

Common Infection Sites & Their Symptoms

• Urinary Tract Infection (UTI): Dysuria, urgency, flank pain, fever, cloudy or foul‑smelling urine.
• Pneumonia: Cough (sometimes productive of rusty or green sputum), shortness of breath, chest pain, high fever, chills, confusion (especially in older adults).
• Bloodstream Infection (Sepsis): Fever or hypothermia, rapid heart rate, low blood pressure, altered mental status, warm or clammy skin.
• Wound/ Surgical Site Infection: Redness, swelling, pain, pus or foul odor from the incision, fever.
• Abscesses (intra‑abdominal, liver, brain): Localized pain, fever, nausea/vomiting, neurological deficits if brain involvement.

Note: In immunocompromised patients, classic signs such as fever may be blunted.

Causes and Risk Factors

CRKP infections arise when a patient is exposed to a carbapenem‑resistant strain and the bacterium overcomes the host’s defenses.

Primary Causes

• Antibiotic pressure: Overuse or inappropriate use of carbapenems and other broad‑spectrum antibiotics selects for resistant organisms.
• Horizontal gene transfer: Resistance genes (e.g., KPC, NDM, OXA‑48) are carried on plasmids that can move between bacteria, spreading resistance rapidly.

Key Risk Factors

• Recent hospitalization (especially >5 days) or ICU stay.
• Use of invasive devices: central venous catheters, urinary catheters, endotracheal tubes, or feeding tubes.
• Previous exposure to carbapenems, fluoroquinolones, or third‑generation cephalosporins.
• Underlying chronic illnesses: diabetes, chronic kidney disease, chronic lung disease, or cancer.
• Immunosuppression: chemotherapy, organ transplantation, HIV/AIDS, high‑dose steroids.
• Residence in long‑term care facilities or nursing homes.
• Travel to regions with high CRKP prevalence (e.g., Southern Europe, the Middle East, parts of Asia).<sup>[3]</sup>

Diagnosis

Early, accurate diagnosis is critical because delayed appropriate therapy worsens outcomes.

Laboratory Tests

• Culture & Sensitivity: Samples from blood, urine, sputum, wound swabs, or other sterile sites are cultured. Automated systems (e.g., VITEK 2, MALDI‑TOF) identify Klebsiella and determine susceptibility. Carbapenem resistance is flagged when minimum inhibitory concentrations (MICs) exceed CLSI breakpoints.
• Molecular Testing: PCR assays detect carbapenemase genes (KPC, NDM, VIM, IMP, OXA‑48). Some hospitals use rapid multiplex panels (e.g., FilmArray) that deliver results in ≤1 hour.
• Phenotypic Confirmatory Tests: Modified Hodge test, Carba NP test, or the metallo‑β‑lactamase (MBL) Etest confirm carbapenemase production.

Imaging (when indicated)

• Chest X‑ray or CT scan for pneumonia.
• Ultrasound/CT abdomen for urinary or intra‑abdominal infections.
• MRI brain for suspected meningitis or brain abscess.

Clinical Scoring

Sepsis screening tools (e.g., qSOFA, SIRS) help identify patients who need urgent intervention while awaiting microbiology results.

Treatment Options

Because CRKP is resistant to carbapenems, therapy relies on older agents, newer β‑lactam/β‑lactamase inhibitor combos, and individualized susceptibility data.

First‑Line Antimicrobial Options (based on susceptibility)

• Polymyxins: Colistin (CMS) or polymyxin B – effective but nephro‑ and neuro‑toxic; monitor kidney function and drug levels.
• Tigecycline: Useful for soft‑tissue and intra‑abdominal infections; caution in bloodstream infections due to low serum concentrations.
• Fosfomycin: Intravenous formulation (often combined with another agent) can be active against some CRKP isolates.
• Novel β‑lactam/β‑lactamase inhibitors:
  • Ceftazidime‑avibactam (active against KPC‑producing strains).
  • Meropenem‑vaborbactam (approved for KPC‑producing CRKP).
  • Imipenem‑relebactam (useful for some carbapenemase‑negative CRKP).
• Combination Therapy: Frequently recommended (e.g., colistin + meropenem‑vaborbactam or tigecycline + fosfomycin) to improve bacterial killing and prevent resistance development.

Adjunctive Measures

• Source control: Removal of infected catheters, drainage of abscesses, debridement of necrotic tissue.
• Supportive care: Fluid resuscitation, vasopressors for septic shock, oxygen therapy, renal replacement therapy if needed.

Duration of Therapy

Typically 7–14 days for uncomplicated UTIs, 10–14 days for pneumonia, and 14–21 days for bloodstream infections or deep‑seated infections, guided by clinical response and repeat cultures.

Lifestyle & Non‑Pharmacologic Strategies

• Optimize nutrition to support immune function.
• Maintain adequate hydration.
• Engage in gentle physical activity as tolerated to improve circulation and lung function.

Living with Klebsiella pneumoniae (Carbapenem‑Resistant)

Surviving a CRKP infection often means ongoing vigilance to prevent recurrence and manage the side effects of potent antibiotics.

Medication Management

• Keep an up‑to‑date medication list; share it with every healthcare provider.
• Attend all follow‑up appointments for repeat cultures and renal/hepatic function testing.
• Report new symptoms (e.g., hearing loss with colistin) promptly.

Home Care Tips

• Hand hygiene: Wash hands with soap for at least 20 seconds before and after touching any wound, catheter, or bathroom fixtures.
• Environmental cleaning: Disinfect high‑touch surfaces (doorknobs, light switches, bathroom fixtures) using EPA‑registered agents effective against gram‑negative bacteria.
• Catheter care: If you have an indwelling urinary catheter, follow sterile technique for bag changes and keep the drainage bag below bladder level.
• Nutrition: Aim for a balanced diet rich in protein, vitamin C, zinc, and probiotics (consult your doctor before starting probiotics).
• Vaccinations: Stay current with influenza, pneumococcal (PCV15 or PCV20), and COVID‑19 vaccines to reduce secondary infections.

Psychosocial Support

Living with a multidrug‑resistant infection can be stressful. Consider counseling, support groups, or patient‑advocacy organizations such as the CDC’s Antibiotic Resistance Action Center.

Prevention

Because CRKP spreads mainly in healthcare settings, prevention hinges on rigorous infection‑control practices.

For Patients & Families

• Practice meticulous hand washing or use alcohol‑based hand rubs.
• Ask healthcare workers whether they have performed hand hygiene before contact.
• Avoid unnecessary antibiotics; discuss risks and benefits with your clinician.
• Limit contact with individuals who have active infections unless proper protective equipment is used.

For Healthcare Facilities

• Implement contact precautions (gown, gloves) for patients known or suspected to carry CRKP.
• Perform active surveillance cultures in high‑risk units (ICU, transplant wards).
• Adopt antimicrobial stewardship programs to curb carbapenem overuse.
• Ensure proper disinfection of reusable equipment (ventilators, endoscopes).
• Educate staff regularly about emerging resistance mechanisms.

Complications

If CRKP infection is not promptly controlled, several serious complications can develop:

• Septic shock: Life‑threatening drop in blood pressure requiring vasopressors.
• Acute respiratory distress syndrome (ARDS): Severe lung injury leading to respiratory failure.
• Acute kidney injury: Often exacerbated by nephrotoxic drugs like colistin.
• End‑organ damage: Myocardial dysfunction, hepatic failure, or coagulopathy.
• Persistent bacteremia: Can seed distant sites, causing metastatic infections (e.g., endocarditis, osteomyelitis).
• Prolonged hospitalization and increased healthcare costs: Median excess cost per CRKP infection in U.S. hospitals exceeds $30,000.<sup>[4]</sup>

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. “Antibiotic Resistance Threats in the United States, 2023.” CDC.gov.
2. World Health Organization. “Global priority list of antibiotic‑resistant bacteria to guide research, discovery, and development of new antibiotics.” 2022.
3. European Centre for Disease Prevention and Control. “Surveillance of antimicrobial resistance in Europe 2022.” ECDC.
4. PubMed. “Economic burden of carbapenem‑resistant Enterobacteriaceae infections in the United States.” *Clin Infect Dis*. 2021;73(6):1018‑1025. doi:10.1093/cid/ciaa779.

```